GRAZOPREVIR POTASSIUM HCV NS3 NS4A protease inhibitor Anti-hepatitis C virus drug

Grazoprevir is a second-generation macrocyclic NS3/NS4A hepatitis C virus (HCV) protease inhibitor with broad activity across multiple genotypes of the HCV. Results of phase II and III studies have been promising across various patient populations, including HIV/HCV coinfected patients, patients with and without cirrhosis who have failed prior therapy, and patients with chronic kidney disease. Grazoprevir is administered once daily as a 100-mg dose and will be available as a fixed-dose combination with elbasvir 50 mg. This review outlines in vivo and in vitro studies, pharmacodynamics and safety, and relevant clinical studies for this promising drug.